JCJohannes Camp

Johannes Camp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Johannes Camp has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Siegbert Rieg

    Universitätsklinikum Freiburg, Deutschland

    6 shared publications
  • Siegbert Rieg

    German Centre for Infection Research (DZIF), Braunschweig, Germany

    5 shared publications
  • Berit Lange

    Helmholtz-Zentrum für Infektionsforschung, Braunschweig, Germany

    3 shared publications
  • Harald Seifert

    Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Medical Faculty and University Hospital of Cologne, Cologne, Germany

    3 shared publications
  • Winfried V. Kern

    Division of Infectious Diseases, Department of Medicine II, Medical Centre-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    3 shared publications
  • Achim J Kaasch

    Institute of Medical Microbiology and Hospital Hygiene, University Hospital, Faculty of Medicine, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

    2 shared publications

Latest Publications

  • Die orale Sequenztherapie der Endokarditis: Aktuelle Evidenz und praktische Umsetzung

    by Johannes Camp, Philipp Mathé, Marie Leibenguth, Siegbert Rieg

    Was ist neu?: Jahrzehntelang war die prolongierte intravenöse Antibiotika-Gabe Mittel der Wahl bei infektiöser Endokarditis. Dieses Paradigma kann angesichts neuer Forschungsergebnisse so nicht mehr aufrechterhalten werden. In der POET-Studie wurde gezeigt, dass bei ausgewählten Patient*innen mit linksseitiger Endokarditis eine orale Sequenztherapie der fortgesetzten intravenösen Behandlung nicht unterlegen ist und langfristig sicher angewendet werden kann. Ergänzende pharmakokinetische Analysen, Subgruppen-Untersuchungen sowie Daten aus Dänemark, Deutschland und den USA stützen diese Strategie auch außerhalb kontrollierter Studien. In der Praxis ist die Umsetzung bislang zurückhaltend, da häufig noch Unsicherheiten bezüglich der Patientenselektion, dem optimalen Wechselzeitpunkt und geeigneten Regimen bestehen. Entscheidend ist die klinische Beurteilung im Einzelfall. Ist der Patient klinisch stabil, gibt es Hinweise auf mögliche Komplikationen? In der Praxis hat sich gezeigt, dass eine orale Sequenztherapie in der 3. Behandlungswoche in vielen Fällen einen guten Zeitpunkt darstellt. Amoxicillin, Fluorchinolone, Linezolid und Cotrimoxazol, ggf. mit Rifampicin, werden als Monotherapie oder in Kombination eingesetzt, abhängig vom Erregertyp.

  • Open Access

    Frequent high-level rifaximin resistance in Escherichia coli associated with long-term treatment of patients with liver cirrhosis: a prospective, controlled study

    by L. Boll, W. V. Kern, S. Schuster, M. Schultheiß, C. Schneider, M. Vavra, R. Thimme, S. Rieg, J. Camp

    We conducted a prospective, controlled study to assess the prevalence of high-level rifaximin resistance in intestinal Escherichia coli (E. coli ) among patients with liver cirrhosis (LC). Rectal swabs were collected from consenting adult LC patients at Freiburg University Medical Center. Swabs were cultured on MacConkey agar plates supplemented with rifaximin at two concentrations (32 µg/mL and 256 µg/mL), and pink/red colonies were identified as E. coli using standard methods. Minimum inhibitory concentrations (MICs) of rifaximin and a panel of additional agents were determined using microdilution assays. Of the 100 patients enrolled, 49 received rifaximin (median duration 22 weeks), and 51 served as controls. Patients receiving rifaximin had more advanced LC (Child B/C, 75% vs. 50%) and more frequent concurrent antibiotic use (22% vs. 12%). High-level rifaximin-resistant E. coli strains were recovered from 67% (33/49) of rifaximin-treated patients, compared to 12% (6/51) of controls ( P < 0.001). Cross-resistance to rifampicin was complete, with no clear associations with other resistance phenotypes. A subset of five high-level resistance swabs was assessed for homogeneity of colonization by randomly picking E. coli strains from a non-supplemented MacConkey agar plate. Homogeneous colonization with high-level rifaximin-resistant E. coli was found in 80% of cases. The prevalence of high-level rifaximin-resistant intestinal E. coli in LC patients on long-term rifaximin treatment is extremely high (67% vs. 12%). While rifaximin may remain effective in preventing hepatic encephalopathy (HE), its potential use in preventing spontaneous bacterial peritonitis might be severely limited by the emergence of resistance. IMPORTANCE: This study highlights the emergence of antibiotic-resistant E. coli as an important consequence of long-term rifaximin use in patients with liver cirrhosis: the development of antibiotic resistance in gut bacteria. Rifaximin is commonly used to prevent complications like hepatic encephalopathy (HE) by targeting gut bacteria. However, this research shows that prolonged use can lead to the emergence of highly resistant E. coli strains, potentially compromising the drug’s effectiveness and limiting its utility in preventing HE and infections, such as spontaneous bacterial peritonitis. By identifying specific resistance patterns and genetic mutations, this study highlights the need for cautious use of rifaximin and further research into balancing its benefits with the risks of resistance. These findings contribute to a broader understanding of how antibiotics affect gut bacteria over time and offer a basis for exploring strategies to preserve the effectiveness of this important medication for patients with advanced liver disease.


  • Open Access

    Early oral switch therapy for infective endocarditis: An international cross-sectional survey on current use in clinical practice

    by Philipp Mathé, Daniel Hornuss, Roland Giesen, Johannes Camp, Burcu Isler, Michele Bartoletti, Brigitte Lamy, Laura Escolà-Vergé, José Maria Miró Meda, Siegbert Rieg


  • Open Access

    Longterm efficacy of a patient focused intervention in patients with asplenia– a three year follow-up of the PrePPS trial

    by Johannes Camp, Valerie Heine, Marianne Bayrhuber, Natascha Anka, Manuela Glattacker, Erik Farin-Glattacker, Siegbert Rieg

    Objectives: This study aimed to reassess the long-term impact of a Health Action Process Approach (HAPA)-informed intervention on guideline adherence among asplenic patients and their physicians, three years post-intervention. Methods: This follow-up study was conducted within the framework of the interventional PrePSS (Prevention of Postsplenectomy Sepsis Score) study. Patients aged 18 or older with anatomical asplenia were in enrolled in a prospective controlled, two-armed historical control group design. The intervention group received tailored educational materials, medical alert cards, and a telephonic HAPA-based intervention. A telephonic follow-up assessment was conducted three years post-intervention, evaluating adherence to preventive measures using the PrePSS-score (range 0–10) and propensity-score based overlap weighting. Results: Out of 106 patients who had received the intervention, 79 (75%) completed the three-year follow-up. The PrePSS-scores further increased compared to six months post-intervention (median of 8.08 points vs 7.60 points), with notable improvements in vaccination coverage and availability of emergency antibiotics. Only four participants reported severe infections requiring hospitalization, none of which were typical of post-splenectomy sepsis. 47/79 (59%) of participants contracted SARS-CoV2 but clinical courses were mild with only one patient needing hospital and ICU treatment. Conclusions: Patients who had received our novel telephonic intervention exhibited significant and sustained improvement in adherence to guideline-based preventive measures at three years post intervention. HAPA-based interventions may yield more sustained effects than traditional nudging strategies.

  • Open Access

    Partial oral treatment of infective endocarditis in real-world settings – an in-depth analysis of the prospectively evaluated German DERIVE cohort

    by Johannes Camp, Klara Nüßle, Noemi Deyhle, Philipp Mathé, Daniel Hornuss, Sebastian Grundmann, Alexander Asmussen, Alicja Zientara, Wolfgang Bothe, Kirsten Schmidt-Hellerau, et al.


  • Open Access

    In Which Patients Do the 2023 Duke-ISCVID Criteria for Infective Endocarditis Increase the Diagnosis of “Definite Endocarditis”?—A Preliminary Analysis in the Prospectively Evaluated DERIVE Cohort

    by Kirsten Schmidt-Hellerau, Johannes Camp, Philipp Alexander Marmulla, Siegbert Rieg, Norma Jung

    Background/Objectives: Recently, an update of the Duke criteria for the diagnosis of infectious endocarditis has been published: the 2023 Duke-ISCVID criteria. To gain an insight into which proportion of patients are affected by the new criteria, and which criteria might be the most relevant for the expected increase in sensitivity, we analysed data from a registry of cardiovascular infections. Methods: The 2023 Duke-ISCVID criteria were applied to patients who were diagnosed with and treated for endocarditis after having been classified as “possible” endocarditis according to the 2015 ESC Modified Duke criteria. In patients thus newly classified as “definite endocarditis”, diagnostic factors leading to this reclassification were described. Results: Of 397 patients, 48 (12%) did not fulfil the definition “definite infectious endocarditis” according to the 2015 ESC Modified Duke criteria. Of these, six (13%) fulfilled the definition when the 2023 Duke-ISCVID criteria were applied. A main factor triggering this reclassification was the consideration of microorganisms identified using valve PCR. Conclusions: As expected, the sensitivity of the new 2023 Duke-ISCVID criteria is increased in this cohort, mainly through the incorporation of new diagnostic methods in the criteria. Further studies are required to assess the effect on specificity in detail.


  • Open Access

    Efficacy of a novel patient-focused intervention aimed at increasing adherence to guideline-based preventive measures in asplenic patients: the PrePSS trial

    by Johannes Camp, Marianne Bayrhuber, Natascha Anka, Valerie Heine, Manuela Glattacker, Erik Farin-Glattacker, Siegbert Rieg

    Purpose To determine whether a novel intervention improves the adherence to guideline-based preventive measures in asplenic patients at risk of post-splenectomy sepsis (PSS). Methods We used a prospective controlled, two-armed historical control group design to compare a novel, health action process approach (HAPA)-based telephonic intervention involving both patients and their general practitioners to usual care. Eligible patients were identified in cooperation with the insurance provider AOK Baden-Wuerttemberg, Germany. Patients with anatomic asplenia (n = 106) were prospectively enrolled and compared to a historical control group (n = 113). Comparisons were done using a propensity-score-based overlap-weighting model. Adherence to preventive measures was quantified by the study-specific ‘Preventing PSS score’ (PrePSS score) which includes pneumococcal and meningococcal vaccination status, the availability of a stand-by antibiotic and a medical alert card. Results At six months after the intervention, we estimated an effect of 3.96 (95% CI 3.68–4.24) points on the PrePSS score scale (range 0–10) with mean PrePSS scores of 3.73 and 7.70 in control and intervention group, respectively. Substantial improvement was seen in all subcategories of the PrePSS score with the highest absolute gains in the availability of stand-by antibiotics. We graded the degree of participation by the general practitioner (no contact, short contact, full intervention) and noted that the observed effect was only marginally influenced by the degree of physician participation. Conclusions Patients who had received the intervention exhibited a significantly higher adherence to guideline-based preventive measures compared to the control group. These data suggest that widespread adoption of this pragmatic intervention may improve management of asplenic patients. Health insurance provider-initiated identification of at-risk patients combined with a patient-focused intervention may serve as a blueprint for a wide range of other preventive efforts leading to patient empowerment and ultimately to better adherence to standards of care.


  • Impact of neutropenia on clinical manifestations and outcome of Staphylococcus aureus bloodstream infection: a propensity score-based overlap weight analysis in two large, prospectively evaluated cohorts

    by Johannes Camp, Tim Filla, Lina Glaubitz, Achim J. Kaasch, Frieder Fuchs, Matt Scarborough, Hong Bin Kim, Robert Tilley, Chun-Hsing Liao, Jonathan Edgeworth, et al.


  • Impact of Immunosuppressive Agents on Clinical Manifestations and Outcome of Staphylococcus aureus Bloodstream Infection: A Propensity Score–Matched Analysis in 2 Large, Prospectively Evaluated Cohorts

    by Johannes Camp, Lina Glaubitz, Tim Filla, Achim J Kaasch, Frieder Fuchs, Matt Scarborough, Hong Bin Kim, Robert Tilley, Chun-Hsing Liao, Jonathan Edgeworth, et al.

    Staphylococcus aureus bloodstream infection (SAB) is a common, life-threatening infection. The impact of immunosuppressive agents on the outcome of patients with SAB is incompletely understood. Data from two large prospective, international, multicenter cohort studies (INSTINCT and ISAC) between 2006 and 2015 were analyzed. Patients receiving immunosuppressive agents were identified and a 1:1 propensity score (PS) matched analysis was performed to adjust for baseline characteristics of patients. Overall survival and time to SAB-related late complications (SAB relapse, infective endocarditis, osteomyelitis, or other deep-seated manifestations) were analyzed by Cox regression and competing risk analyses, respectively. This approach was then repeated for specific immunosuppressive agents (corticosteroids [CSMT] and immunosuppressive agents other than steroids [IMOTS]). Of 3,188 analyzed patients, 309 were receiving immunosuppressive treatment according to our definitions and were matched to 309 non-immunosuppressed patients. After PS matching, baseline characteristics were well balanced. In the Cox regression analysis, we observed no significant difference in survival between the two groups (death during follow-up: 105/309 (33.9 %) immunosuppressed patients vs. 94/309 (30.4 %) non-immunosuppressed, hazard ratio 1.20 (95% CI 0.84–1.71). Competing risk analysis showed a cause-specific hazard ratio (CSHR) of 1.81 (95% CI 0.85–3.87) for SAB-related late-complications in patients receiving immunosuppressive agents. CSHR was higher in patients taking IMOTS (3.69; 95% CI 1.41–9.68). Immunosuppressive agents were not associated with an overall higher mortality. The risk for SAB-related late complications in patients receiving specific immunosuppressive agents such as IMOTs warrants further investigations.


  • Limited Multidrug Resistance Efflux Pump Overexpression among Multidrug-Resistant Escherichia coli Strains of ST131

    by Johannes Camp, Sabine Schuster, Martina Vavra, Tobias Schweigger, John W. A. Rossen, Sandra Reuter, Winfried V. Kern

    Gram-negative bacteria partly rely on efflux pumps to facilitate growth under stressful conditions and to increase resistance to a wide variety of commonly used drugs. In recent years E. coli ST131 has emerged as a major cause of extraintestinal infection frequently exhibiting an MDR phenotype. The contribution of efflux to MDR in emerging E. coli MDR clones however, is not well studied. We characterized strains from an international collection of clinical MDR-E. coli isolates by MIC testing with and without the addition of the AcrAB-TolC efflux inhibitor 1-(1-naphthylmethyl)-piperazine (NMP). MIC data for 6 antimicrobial agents and their reversion by NMP were analyzed by Principal Component Analysis (PCA). PCA revealed a group of 17/34 MDR-E. coli exhibiting increased susceptibility to treatment with NMP suggesting an enhanced contribution of efflux pumps to antimicrobial resistance in these strains (termed “enhanced efflux phenotype” [EEP]). Only 1/17 EEP strains versus 12/17 non-EEP MDR strains belonged to the ST131 clonal group. Whole-genome sequencing revealed marked differences in efflux-related genes between EEP and control strains, with the majority of notable amino-acid substitutions occurring in AcrR, MarR and SoxR. qRT-PCR of multiple efflux-related genes showed significant overexpression of the AcrAB-TolC-system in EEP strains, whereas in the remaining strains we found enhanced expression of alternative efflux proteins. We conclude that a proportion of MDR E. coli exhibit an EEP, which is linked to an overexpression of the AcrAB-TolC-efflux-pump and a distinct array of genomic variations. Members of ST131, although highly successful, are less likely to exhibit the EEP.